{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-068298","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2024-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.373311+00:00","generated_at":"2026-06-01T06:41:00.384552+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Amarin CEO resigns; large PBM to drop Vascepa coverage July 1, affecting 25% of US volume","bullets":["CEO Pat Holt resigned; Aaron Berg appointed as President & CEO effective June 4, 2024.","Holt will provide consulting services through July 3, 2024 in exchange for his base salary.","A large national PBM will exclude Vascepa from commercial national formularies effective July 1, 2024.","Affected formularies represent ~25% of aggregate US Vascepa prescription volume; Medicare Part D unaffected."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-068298","json":"https://secwatch.observer/filing/0000950170-24-068298.json","markdown":"https://secwatch.observer/filing/0000950170-24-068298.md","text":"https://secwatch.observer/filing/0000950170-24-068298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017024068298/0000950170-24-068298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017024068298/amrn-20240603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:41:00.384552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38252225ad","claim":"Aaron Berg was appointed as President and Chief Executive Officer at AMARIN CORP PLCUK.","evidence_excerpt":"Aaron Berg, who has been serving as the Company’s Executive Vice President, President U.S., has replaced Mr. Holt as President and Chief Executive Officer, effective June 4, 2024 (the “CEO Start Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017024068298/0000950170-24-068298-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"76f4b3c397","claim":"Aaron Berg was appointed as Member of the Board of Directors at AMARIN CORP PLCUK.","evidence_excerpt":"Mr. Berg has been appointed as a member of the Company’s board of directors (the “Board”), effective as of the CEO Start Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017024068298/0000950170-24-068298-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"f7863f717f","claim":"Patrick Holt resigned as President and Chief Executive Officer at AMARIN CORP PLCUK.","evidence_excerpt":"On June 3, 2024, Patrick Holt notified Amarin Corporation plc (the “Company”) of his decision to voluntarily resign as President and Chief Executive Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017024068298/0000950170-24-068298-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}